FinTok developed by Fiadm s.r.o. · future of webapps

Ostatné · NTRA

Natera, Inc.

420,09 9,74 (+2,37 %) aktualizované práve teraz
1 týždeň+2,0 %
1 mesiac+28,0 %
3 mesiace+48,0 %
1 rok+151,0 %
52t minimum167,35
52t maximum420,09
RSI 1481
SMA 50334,23
SMA 200250,02

Fundamenty firmy Healthcare · Diagnostics & Research · United States

Hodnotenie 0–10, vypočítané z údajov firmy

Finančná siladlh voči vlastnému kapitálu, likvidita
10
Ziskovosťmarže, návratnosť kapitálu (ROE)
0
Rastrast tržieb a ziskov
10
OcenenieP/E, PEG, P/B – vyššie = lacnejšie
0

Orientačné skóre v štýle GuruFocus – nie je to odporúčanie.

Analytici 22 hodnotení

silný nákup

Najnižší cieľ
280,00
Priemerný cieľ
361,16
Najvyšší cieľ
475,00
Potenciál
−14,0 %
5162

silný nákup · nákup · držať · predaj · silný predaj

Oceniť v DCF kalkulačke →
Trhová kapitalizácia ?60,6 mld. P/E ?– P/E budúce ?-3 060,1 PEG ?– P/B ?33,1 EV/EBITDA ?-259,8 Dividendový výnos ?– Čistá marža ?-7,1 % ROE ?-12,5 % Dlh / vlastný kapitál ?13 % Rast tržieb ?+37,7 % Rast ziskov ?– Voľný cash flow ?104,0 mil. Tržby ?2,7 mld. Beta ?1,50 Podiel inštitúcií ?97 %

Odhad zisku na akciu (EPS)

ObdobieOdhadRozpätiePred rokomRast
tento štvrťrok-0,24-0,61–0,13-0,64+61,7 %
budúci štvrťrok-0,09-0,34–0,310,36−125,0 %
tento rok-1,41-2,02–-0,63-1,52+7,1 %
budúci rok-0,14-1,93–1,74-1,41+90,3 %

Odhad tržieb

ObdobieOdhadPred rokomRast
tento štvrťrok707,1 mil.592,2 mil.+19,4 %
budúci štvrťrok749,3 mil.665,5 mil.+12,6 %
tento rok2,9 mld.2,3 mld.+26,2 %
budúci rok3,5 mld.2,9 mld.+20,6 %

Nákupy a predaje manažérov insider

KtoČoHodnotaDátum
Rabinowitz MatthewOfficer and Director predaj 34,8 mil.15.09.
Rabinowitz MatthewOfficer and Director predaj 16,4 mil.11.09.
Moshkevich SolomonOfficer predaj 5,9 mil.02.09.
Chapman Steven LeonardChief Executive Officer predaj 545 04101.09.
Fesko JohnPresident predaj 2,1 mil.10.08.
Sheena JonathanDirector predaj 2,0 mil.10.08.
Sheena JonathanDirector predaj 2,9 mil.07.08.
Rabinowitz MatthewOfficer and Director predaj 641 80007.08.
Fesko JohnPresident odmena v akciách –06.08.
Brophy Michael BurkesChief Financial Officer predaj 216 03004.08.
Rabinowitz Daniel AOfficer predaj 89 50803.08.
Fesko JohnPresident predaj 79 05703.08.

Predaje manažérov sú bežné (dane, diverzifikácia); nákupy z vlastných peňazí bývajú silnejší signál.

Kto vlastní akcie

Slávni investori: Stanley Druckenmiller · 19.9 % Cathie Wood · 1.2 % Ray Dalio · 0.0 %

JPMORGAN CHASE & CO8,93 %

Blackrock Inc.7,57 %

Price (T.Rowe) Associates Inc6,26 %

Vanguard Capital Management LLC4,32 %

Vanguard Portfolio Management LLC4,01 %

FMR, LLC3,78 %

Wellington Management Group, LLP2,80 %

State Street Corporation2,54 %

O firme (popis z Yahoo Finance, anglicky)

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

https://www.natera.com ↗

Názor AI

Krátke zhodnotenie trendu, správ a blížiacich sa udalostí.

Technické signály

Odporúčania

K tomuto aktívu zatiaľ nemáme odporúčanie.

Predikcie

Žiadne predikcie.

Súvisiace správy

Žiadne správy so značkou NTRA.